Pulmonary Hypertension (PH) Completed Phase 3 Trials for Ambrisentan (DB06403)

Also known as: Hypertension, Pulmonary / Pulmonary; Hypertension / Pulmonary hypertension / Hypertension Pulmonary / Pulmonary hypertensions / Pulmonary hypertension NOS

IndicationStatusPhase
DBCOND0051788 (Pulmonary Hypertension (PH))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00554619A Study to Evaluate GSK1325760A - a Long-Term Extension StudyTreatment
NCT01178073A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)Treatment
NCT00091598ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)Treatment
NCT00380068Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary HypertensionTreatment